The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High intratumoral tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): Results from a prospective trial using baseline C11-labeled alpha-methyl tryptophan (C11-AMT) PET imaging for response prediction.
 
Jorge D. Oldan
Honoraria - Wolters Kluwer
 
David W. Ollila
Stock and Other Ownership Interests - Johnson & Johnson
 
Ben C. Giglio
No Relationships to Disclose
 
Eric Smith
Consulting or Advisory Role - Covance
 
Deeanna M. Bouchard
No Relationships to Disclose
 
Marija Ivanovic
No Relationships to Disclose
 
Yueh Z. Lee
No Relationships to Disclose
 
Frances A. Collichio
Research Funding - Amgen; GlaxoSmithKline (Inst); Merck; Novartis
Other Relationship - ACGME
 
Michael O. Meyers
No Relationships to Disclose
 
Diana E. Wallack
No Relationships to Disclose
 
Amir H. Khandani
No Relationships to Disclose
 
Amber Abernathy-Leinwand
No Relationships to Disclose
 
Patricia K. Long
No Relationships to Disclose
 
Jennifer Ashley Ezzell
No Relationships to Disclose
 
Dimitri G. Trembath
No Relationships to Disclose
 
Zibo Li
No Relationships to Disclose
 
Terence Z. Wong
Honoraria - Wake Radiology
Consulting or Advisory Role - Lucerno Dynamics
 
Stergios J. Moschos
Consulting or Advisory Role - Amgen; EMD Serono; Novartis; Sanofi
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen (Inst); Genentech/Roche (Inst); Lexicon (Inst); Merck Sharp & Dohme (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis